Jubilant Pharmova Share Price: Shares of Jubilant Pharmova are likely to remain in focus after brokerage firm Nuvama Research reiterated its ‘BUY’ rating on the stock and set a 12-month share price target. Despite trimming near-term estimates due to challenges at the Montreal facility, the brokerage remains optimistic about the company’s long-term growth prospects, driven by strong momentum in its CDMO business.
With the stock recently closing at Rs 1,006, the revised target suggests a potential upside of over 13 per cent from current levels.
The stock closed at Rs 1006 recently. The new target implies an upside of around 13.3 per cent from current levels.
Jubilant Pharmova Ltd on Friday reported a 21 per cent decline in consolidated net profit to Rs 119.3 crore in the March quarter, impacted by exceptional items outgo.
The company had posted a consolidated net profit of Rs 151.3 crore in the corresponding period of the previous fiscal year, Jubilant Pharmova Ltd said in a regulatory filing.
Consolidated total revenue from operations during the quarter stood at Rs 2,290 crore as compared to Rs 1,928.8 crore in the year-ago period.
CDMO business remains the key growth driver
The company’s CDMO-Sterile Injectables (CDMO-SI) business delivered strong 57 per cent growth in the quarter and continues to be the highlight.
“Jubilant’s CDMO business stays an attractive proposition… now has a pipeline of more than 10 molecules, including one large commercial oncology product,” the report highlighted.
The board has recommended a final dividend of Rs 5 per equity share of face value of Re 1 each for the financial year ended March 31, 2026.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions)
